scholarly journals Hepatitis C Virus Infection in HIV Type 1--Infected Individuals Does Not Accelerate a Decrease in the CD4+ Cell Count but Does Increase the Likelihood of AIDS-Defining Events

2005 ◽  
Vol 41 (6) ◽  
pp. 906-911 ◽  
Author(s):  
J. Stebbing ◽  
L. Waters ◽  
S. Mandalia ◽  
M. Bower ◽  
M. Nelson ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Cell Count ◽  
Hepatitis C Virus Infection ◽  
Cd4 Cell Count ◽  
Hiv Type 1 ◽  
Cd4 Cell

Liver/kidney microsome antibody type 1 and hepatitis C virus infection

Hepatology ◽  
1992 ◽  
Vol 16 (3) ◽  
pp. 630-636 ◽  
Author(s):  
Francloise Lunel ◽  
Nisen Abuaf ◽  
Lionel Frangeul ◽  
Patrick Grippon ◽  
Michèle Perrin ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Hepatitis C Virus Infection ◽  
Kidney Microsome

scholarly journals Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system

2019 ◽  
Vol 30 (7) ◽  
pp. 689-695 ◽  
Author(s):  
Jennifer O Lam ◽  
Leo B Hurley ◽  
Scott Chamberland ◽  
Jamila H Champsi ◽  
Laura C Gittleman ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Abuse ◽  
Cell Count ◽  
Hcv Treatment ◽  
Cd4 Cell Count ◽  
Treatment Uptake ◽  
Immunodeficiency Virus ◽  
Cd4 Cell

U.S. guidelines recommend that patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) be prioritized for HCV treatment with direct-acting antiviral agents (DAAs), but the high cost of DAAs may contribute to disparities in treatment uptake and outcomes. We evaluated DAA initiation and effectiveness in HIV/HCV-coinfected patients in a U.S.-based healthcare system during October 2014–December 2017. Of 462 HIV/HCV-coinfected patients, 276 initiated DAAs (70% cumulative proportion treated over three years). Lower likelihood of DAA initiation was observed among patients with Medicare (government-sponsored insurance) versus commercial insurance (adjusted rate ratio [aRR] = 0.62, 95% CI = 0.46–0.84), patients with drug abuse diagnoses (aRR = 0.72, 95% CI = 0.54–0.97), patients with CD4 cell count <200 cells/µl versus ≥500 (aRR = 0.45, 95% CI = 0.23–0.91), and patients without prior HCV treatment (aRR = 0.68, 95% CI = 0.48–0.97). There were no significant differences in DAA initiation by age, gender, race/ethnicity, socioeconomic status, HIV transmission risk, alcohol use, smoking, fibrosis level, HIV RNA levels, antiretroviral therapy use, hepatitis B infection, or number of outpatient visits. Ninety-five percent of patients achieved sustained virologic response (SVR). We found little evidence of sociodemographic disparities in DAA initiation among HIV/HCV-coinfected patients, and SVR rates were high. Efforts are needed to increase DAA uptake among coinfected Medicare enrollees, patients with drug abuse diagnoses, patients with low CD4 cell count, and patients receiving first-time HCV treatment.

HAART is associated with lower hepatic necroinflammatory activity in HIV–hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/μl at the time of liver biopsy

AIDS ◽  
2009 ◽  
Vol 23 (8) ◽  
pp. 971-975 ◽  
Author(s):  
José F Pascual-Pareja ◽  
Alejandra Caminoa ◽  
Javier Larrauri ◽  
Juan González-García ◽  
Maria L Montes ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Cell Count ◽  
Cd4 Cell Count ◽  
Necroinflammatory Activity ◽  
Cd4 Cell

Hepatitis C virus infection-related Type 1 diabetes mellitus

2005 ◽  
Vol 22 (3) ◽  
pp. 340-343 ◽  
Author(s):  
L.-K. Chen ◽  
Y.-C. Chou ◽  
S.-T. Tsai ◽  
S.-J. Hwang ◽  
S.-D. Lee
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Type 1 Diabetes Mellitus ◽  
Hepatitis C Virus Infection

Low prevalence of hepatitis C virus infection in patients with auto-immune hepatitis type 1

1993 ◽  
Vol 8 (5) ◽  
pp. 442-447 ◽  
Author(s):  
EIJI TANAKA ◽  
KENDO KIYOSAWA ◽  
TAKESHI SEKI ◽  
AKIHIRO MATSUMOTO ◽  
TAKESHI SODEYAMA ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Hepatitis C Virus Infection ◽  
Low Prevalence

Serum anti-liver cytosol antibodies type 1 in hepatitis C virus infection

1994 ◽  
Vol 21 (3) ◽  
pp. 480 ◽  
Author(s):  
Jean-Michel Pawlotsky ◽  
Nisen Abuaf ◽  
Chantal Andre ◽  
Lionel Deforges ◽  
Jean Duval ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Hepatitis C Virus Infection ◽  
Liver Cytosol

Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-α and ribavirin treatment for chronic hepatitis C virus infection

2003 ◽  
Vol 64 (5) ◽  
pp. 497-504 ◽  
Author(s):  
Jayaprakash Sreenarasimhaiah ◽  
Andrés Jaramillo ◽  
Jeffrey Crippin ◽  
Mauricio Lisker-Melman ◽  
William C Chapman ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Cd8 T Cell ◽  
Interferon Α ◽  
Hepatitis C Virus Infection ◽  
Cell Responses ◽  
Chronic Hepatitis C Virus
Sign in / Sign up

Export Citation Format

Share Document